Table 3

S100 proteins predict response to RTX treatment

Shows improvement at 6 months
P valueAdjusted
P valueDisease activity
P value
Serum S100A8/A9 0.80.5–––0.9 0.038
Serum S100A12 10.8–1.40.810.7––0.9 0.036
Urine S100A8/A910.8––1.40.9
Urine S100A1210.9–1.30.310.8–1.20.8
Shows improvement at 12 months
Serum S100A8/A90.70.4––1.70.5
Serum S100A1210.7–1.40.910.7–1.50.9
Urine S100A8/A910.7–1.30.810.7–1.40.8
Urine S100A1210.8––1.30.8
Major clinical response at 6 months
Serum S100A8/A9 0.80.4–––0.9 0.036
Serum S100A12 10.7–––0.8 0.03
Urine S100A8/A90.990.7––20.6
Urine S100A1210.8––20.1
Major clinical response at 12 months
Serum S100A8/A90.80.4––1.90.6
Serum S100A120.90.6––1.40.6
Urine S100A8/A90.990.7–1.410.90.6–1.40.7
Urine S100A1210.8––1.30.8
  • Displayed are crude and adjusted ORs for S100 proteins alone and in combination with the outcome of being a responder to RTX. ORs, CIs and p values are displayed. The ‘disease activity’ column displays OR, CI and p value for this variable when S100 proteins and other variables are included as part of the model.

  • Adjusted for age, disease duration, renal disease (outcome ARI), disease activity (outcome higher disease), low C3 or C4 (outcome positive), anti-dsDNA (outcome positive) and steroid dose. Bold=significant for S100 protein.

  • Anti-dsDNA, anti-double-stranded DNA; ARI, acute renal infarction; RTX, rituximab.